±Ð¨|ºtÁ¿17¡GªÎ­D¯g¤Î¬ÛÃö¯e¯fªvÀøªº³Ì·s¶i®i
Obesity and Its Related Diseases in Taiwan

E17-4
ªvÀøªÎ­D¯gÃĪ«ªºµo®i
Pharmacotherapy for Obesity
¼BÀ駻 ³\¶®¶² ªL¤å¤¸1 §d¦Ü¦æ2 ¶À°ê®Ê3
Âù©MÂå°|´_°·Âå¾Ç³¡ ¤¤°êÂåÃĤj¾Çªþ³]Âå°|®aÂå¬ì1 ¦¨¤jªþ³]Âå°|®aÂå¬ì2
»O¤jÂå°|®aÂå¬ì3

¡@¡@ÀHµÛªÎ­D²±¦æ²v³v¦~¼W¥[¥BªÎ­D®e©ö¨Öµo¨ä¥LºC©Ê¯f¡AªÎ­DªºªvÀø¤Î¹w¨¾µ´¹ï¬O·í¤µ·¥¬°­«­nªº½ÒÃD¡AµM¦Ó¡A¤£·í¨Ï¥Î´îªÎÃĪ«¦Ó¾É­P¨Öµo¯gªº°ÝÃD«o¤]®É¦³©Ò»D¡C¤@¯ë¦Ó¨¥¡AÃĪ«ªvÀø¬O»²§U«DÃĪ«ªvÀø¤§¤£¨¬¡C´î­«­p¹º¤¤¡A«DÃĪ«ªvÀø¦pªG¤wºÉ¥þ¤O¡A«o¤´¥¼³º¨ä¥\¡A¤~¥i¦Ò¼{¨Ï¥Î§ÜªÎ­DÃĪ«ªvÀø¡A©Ò¥H´îªÎÃĪ«ªºªvÀø®É¾÷¡B¦X²z¥ÎÃĤΥÎÃĦw¥þ­È±o²`¤J¬ã¨s»P±´°Q¡C

¡@¡@®Ú¾ÚBRFSSªº½Õ¬d³ø§iµo²{¬ü°ê¦³28.3%ªº¨k©Ê¤Î43.6%¤k©Ê¥¿¦bÀ|¸Õ´îªÎ¡A°ê¤ºªº¬ã¨sÅã¥Ü11.7%´¿¸g©Î¥¿¦b¨Ï¥Î´î­«ÃĪ«¡A¨Ï¥Î¦èÃĪ̦û55.6%¡C´îªÎÃĪ«ªø´Á¥H¨Ó¦]¬°¦UºØÃĪ«¤£¨}¤ÏÀ³¡Aµ´¤j³¡¤Àªº´îªÎÃĪ«¨ì³Ì«á³£¾D¹J¨ì¤U¬[°±¥Îªº©R¹B¡A¨Ò¦p¦w«D¥L©R¡]Amphetamine¡^¡B¡uªâ×ô¡v¡]Fen-Phen¡^©MPPA¡]Phenypropanolamine¡^µ¥¡C

¡@¡@¥Ø«e¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^®Ö­ã¤§´îªÎÃĪ«¡A¥u¦³¿Õ¬ü´@¡]Reductil„µ¡GSibutramine¡^¤Îù¤óÂA¡]Xenical„µ¡GOrlistat¡^¥iªø´Á¨Ï¥Î¡F¿Õ¬ü´@¦P®É¨ã¦³§í¨î¤¤¼Ï¯«¸g¨t²Îªº¥¿µÇ¤W¸¢¯À¡B¦å²M¯À©M¦h¤ÚÓi¦A§l¦¬¡A³y¦¨¹¡¨¬·P¡A¶i¦Ó´î¤Ö­¹ª«ªºÄá¨ú¡AFDA©ó1997¦~®Ö­ã¥Î©óªvÀøªÎ­D¯g¡A¥xÆW©ó2002¦~¤W¥«¡A¦ý2010¦~Scout¬ã¨sµo²{¹ï©óÄY­«°ª¦åÀ£¤ÎºC©Ê¤ßŦ¯f±wªÌ¡A¨Ï¥Î«á·|¼W¥[¤ß¦åºÞ¯e¯f­·ÀI¡A¼Ú¬w©ó2010¦~¦~ªì¤w¼È®É¸T¥Î¦¹ÃÄ¡A¬ü°êFDA¥¿¼f·Vµû¦ô¬O§_Ä~Äò®Ö­ã¨Ï¥Î¡Cù¤óÂA¬°¤£¸g¥þ¨­§l¦¬ªº¸z­G¹D¯×ªÕ¤À¸Ñ»Ã¯À§í¨î¾¯¡AFDA©ó1999¦~®Ö­ã¥Î©óªvÀøªÎ­D¯g¡A2000¦~¦b¥xÆW¤W¥«¡A¥Ø«e¤]¥X²{¤@¥b¾¯¶qªºOTCÃĪ«±dÅÖ¦ñ¡]Alli¡^¡CªvÀøªÎ­D¯gªº·sÃĥثe¤´«ùÄò¶i¦æ¤¤¡A³Ìªñ¦b¯«¸g¤¤¼Ï±±¨îÄá­¹ªº¾÷Âà¬ã¨s¤WªºÅãµÛ¶i¨B¡A¦³¤£¤Ö¤¤¼Ï©Ê§ÜªÎ­DÃĪ«±N³Q³Q¬ãµo¥X¨Ó¡A¥¼¨ÓªÎ­D±M¬ìÂå®v¥²¶·°w¹ïÃĪ«¨Ï¥Îªº¾A·í©Ê¡B¦hºØÃĪ«¦X¨Ö¨Ï¥Îªº¥æ¤¬§@¥Î¤ÎÃĪ«¤§¤£¨}¤ÏÀ³µ¥¡A¶i¤@¨B»{ÃѤF¸Ñ¡A¥H½T«O°ê¤H¥ÎÃĦw¥þ¡C